(Q69225952)
English
Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative S
scientific article published on 01 September 1989
Statements
Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA (English)
A E Arnold
R W Brower
D Collen
G A van Es
J Lubsen
M L Simoons
1 September 1989